Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Clears First-Of-A-Kind Breast Cancer Recurrence Test

This article was originally published in The Gray Sheet

Executive Summary

Dutch firm Agendia's MammaPrint test for predicting breast cancer recurrence set regulatory precedent Feb. 6 when it received 510(k) clearance
Advertisement

Related Content

Financings In Brief
Agendia Boasts Expanded Clearance, Reimbursement For Breast Cancer Test
Financings In Brief
Newest Breast Cancer Biomarkers Will Predict Therapy Outcomes
People In Brief
Final FDA Genetic Test Guidelines Respond To Some Industry Critiques
Regulatory News In Brief
Exagen Files First Of Six Planned 510(k)s For Genomic Test Kits
Laboratory Stakeholders Urge FDA To Ditch IVDMIA Guidance, Pursue Rule
Laboratory Stakeholders Urge FDA To Ditch IVDMIA Guidance, Pursue Rule
Advertisement
UsernamePublicRestriction

Register

MT024484

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel